ArticleEuropean heart journal. Cardiovascular pharmacotherapy2020
Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients.
Article in European heart journal. Cardiovascular pharmacotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 56 citations in OpenAlex.
- Baseline NT-proBNP levels as a predictor of short-and long-term prognosis in COVID-19 patients: a prospective observational study.BMC infectious diseases · 2024Observational
- Outcomes of COVID-19-Associated Hospitalizations in Geriatric Patients with Dementia in the United States: A Propensity Score Matched Analysis.Geriatrics (Basel, Switzerland) · 2024Article
- Valsartan Mitigates the Progression of Methotrexate-Induced Acute Kidney Injury in Rats via the Attenuation of Renal Inflammation and Oxidative Stress.Journal of inflammation research · 2024Article
- Cardiac Autonomic Function in Long COVID-19 Using Heart Rate Variability: An Observational Cross-Sectional Study.Journal of clinical medicine · 2022Article
- Enzymes in the time of COVID-19: An overview about the effects in the human body, enzyme market, and perspectives for new drugs.Medicinal research reviews · 2022Review
- Impaired Vagal Activity in Long-COVID-19 Patients.Viruses · 2022Article
- COVID-19 and renin angiotensin aldosterone system: Pathogenesis and therapy.Health science reports · 2021Review
- COVID-19, cytokines, inflammation, and spices: How are they related?Life sciences · 2021Review
- The Cross-Talk between Thrombosis and Inflammatory Storm in Acute and Long-COVID-19: Therapeutic Targets and Clinical Cases.Viruses · 2021Article
- Protecting older patients with cardiovascular diseases from COVID-19 complications using current medications.European geriatric medicine · 2021Review
- SARS-CoV-2 Disease Adjuvant Therapies and Supplements Breakthrough for the Infection Prevention.Microorganisms · 2021Review
- COVID-19: imbalance of multiple systems during infection and importance of therapeutic choice and dosing of cardiac and anti-coagulant therapies.Molecular biology reports · 2021Review
- Repurposing of existing FDA approved drugs for Neprilysin inhibition: AnJournal of molecular structure · 2021Article
- A Contemporary View of Natriuretic Peptides in the SARS-CoV-2 Era.Frontiers in physiology · 2021Review
- Inflammation and cardiovascular diseases.Chronic diseases and translational medicine · 2020Article
- Modeling the Molecular Impact of SARS-CoV-2 Infection on the Renin-Angiotensin System.Viruses · 2020Article
- Targeting the renin-angiotensin signaling pathway in COVID-19: Unanswered questions, opportunities, and challenges.Proceedings of the National Academy of Sciences of the United States of America · 2020Review
- The Rationale for Angiotensin Receptor Neprilysin Inhibitors in a Multi-Targeted Therapeutic Approach to COVID-19.International journal of molecular sciences · 2020Review
- The Cross-Talk between Age, Hypertension and Inflammation in COVID-19 Patients: Therapeutic Targets.Drugs & aging · 2020Article
- Repurposing current therapeutics for treating COVID-19: A vital role of prescription records data mining.Drug development research · 2020Article
Corrections and comments
- Comment on
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.